New Research Detects Early Heart Dysfunction in Young Adults with Bipolar Disorder

Cardiovascular disease is the leading cause of premature deaths in patients with bipolar disorder worldwide. In a novel study in young adults (aged 20-45) with bipolar disorder researchers were able to detect subtle (subclinical) abnormalities in how their heart muscle functions and pumps blood before the onset of heart failure by measuring peak systolic strain and myocardial work. The findings in Biological Psychiatry, published by Elsevier, point to new avenues for therapeutic development aimed at preventing progression to heart failure in this at-risk population.

Despite accumulating evidence that cardiovascular disease risk increases during the early stages of bipolar disorder, few studies have investigated cardiac dysfunction in the early course of the illness. This study is the first to uncover that myocardial dysfunction is already evident in patients with bipolar disorder under 45 years of age before the onset of heart failure, suggesting a possible link to underlying coronary vascular dysfunction.

By using indicators sensitive to early detection of subclinical cardiac dysfunction before the onset of heart failure, this study showed that both global and regional peak systolic strain (measuring how much the heart muscle deforms or shortens during a contraction [systole]) and myocardial work (assessing the total work the heart muscle does to pump blood, taking into account both how much it contracts and the pressure it has to pump against) were impaired across left ventricular segments in young adults with bipolar disorder compared to individuals of similar age without psychiatric disorders.

Because the investigators measured regional peak systolic strain and regional myocardial work in accordance with the American Heart Association (AHA) 17-segment model based on the perfusion territories, specific areas of heart muscle supplied with blood by each of the main coronary arteries (i.e., the left anterior descending, left circumflex, and right coronary arteries), the findings of this study suggest an impaired cardiac function in relation to aberrant coronary vascular perfusion in the early course of bipolar disorder.

“Because no study has previously evaluated regional peak systolic strain and regional myocardial work in patients with bipolar disorder using the AHA 17-segment model, this hypothesis-generating study was designed to identify patterns and formulate potential hypotheses for further investigation into the heart–bipolar disorder link,” explains lead investigator Pao-Huan Chen, MD, PhD, Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University; and Department of Psychiatry, and Psychiatric Research Center, Taipei Medical University Hospital.

First author Cheng-Yi Hsiao, MD, Division of Cardiology, Department of Internal Medicine, and Cardiovascular Research Center, Taipei Medical University Hospital; and Taipei Heart Institute and School of Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, adds. “Although there is much evidence suggesting elevated cardiovascular risk in individuals with bipolar disorder, we are still surprised by the findings that even in this young population with bipolar disorder, the myocardial dysfunction extensively involves the left ventricular segments across the perfusion territories of the three major coronary arteries.”

Bipolar disorder is a severe mental illness that often manifests during adolescence and young adulthood. Population-based cohort studies and large-scale meta-analyses have revealed that in addition to experiencing the lifelong burden of mood symptoms, patients are at an approximately two-fold higher risk of heart failure, which is one of the main causes of premature cardiovascular mortality in patients with bipolar disorder.

To clarify the pathophysiology of heart failure in patients with bipolar disorder, future studies should explore the mechanistic pathways leading to coronary vascular dysfunction in this population.

“Following replication in future studies across different samples, the peak systolic strain and myocardial work indices should be incorporated into the cardiovascular assessment for patients with bipolar disorder. This assessment would provide an opportunity to identify and manage cardiac dysfunction as early as possible before the progression of heart failure, while laying a strong foundation for the development of new therapeutics to avoid heart failure and improve life expectancy,” advises Dr. Chen.

John Krystal, MD, Editor of Biological Psychiatry, comments, “Individuals with bipolar disorder have reduced life expectancy relative to the general population by nine to 20 years, and some of this risk may be related to increased risk for cardiovascular disease. This study raises important questions about this risk and potential genetic links between bipolar disorder and cardiac disease, the cardiac impact of psychotropic medications and other environmental factors like diet, exercise, stress, and substance use. It will also be important to understand why women were affected to a greater extent than men."

Notes for editors

The article is "Impaired Global and Regional Peak Systolic Strain and Myocardial Work in Young Adults With Bipolar Disorder,” by Cheng-Yi Hsiao, Tsung-Han Hsieh, Hsin-Yi Lai, Kevin Li-Chun Hsieh, Kuo- Hsuan Chung, Yun-Ru Liu, Shang-Ying Tsai, and Pao-Huan Chen (https://doi.org/10.1016/j.biopsych.2025.06.021). It appears online in Biological Psychiatry, published by Elsevier.

The article is openly available for 60 days at https://www.biologicalpsychiatryjournal.com/article/S0006-3223(25)01295-8/fulltext.

Copies of the full text and additional information are also available to credentialed journalists upon request; please contact Rhiannon Bugno at [email protected]. Journalists wishing to interview the authors should contact Pao-Huan Chen, MD, PhD, at [email protected].

The authors’ affiliations and disclosures of financial and conflicts of interests are available in the article.

John H. Krystal, MD, is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.

This work was supported by the National Science and Technology Council, Taiwan (grant number: NSTC 106-2314-B-038-050-MY3 and NSTC 113-2628-B-038-004-MY3) and the Brain & Behavior Research Foundation (Young Investigator Grant; grant number: 29968).

About Biological Psychiatry

Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms, and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.

The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.

Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 9^th out of 156 Psychiatry titles and 17^th out of 271 Neurosciences titles in Journal Citation Reports^TM, published by Clarivate. The 2024 Impact Factor score for Biological Psychiatry is 9.0.www.sobp.org/journal

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야를 선도하는 글로벌 기업입니다. 100년 넘게 과학과 의료의 발전을 뒷받침하며 인류의 더 나은 미래를 위해 노력해왔습니다. 우리는 전 세계 170개국의 대학 및 기업 연구자, 의사, 간호사, 차세대 보건의료 인력과 교육자들이 중요한 업무를 수행할 수 있도록 지원하고 있습니다. 우리는 신뢰할 수 있는 근거 기반의 과학과 의학 콘텐츠에 첨단 인공지능(AI) 기술을 접목한 핵심 인사이트와 혁신적인 솔루션을 제공함으로써, 이들의 더 나은 성과 달성을 돕고자 합니다. 우리는 제품과 조직 문화 전반에 포용성과 지속 가능성의 가치를 반영하고, 함께하는 커뮤니티와의 협력을 통해 이를 실천해 나가고 있습니다. 엘스비어 재단(Elsevier Foundation)은 세계 곳곳에서 연구 및 보건 분야의 협력 사업을 후원하고 있습니다.

엘스비어는 전문가 및 비즈니스 고객을 위한 정보 기반 분석 및 의사결정 도구를 제공하는 글로벌 기업 RELX의 계열사입니다. 자세한 내용은 www.elsevier.com에서 확인하실 수 있으며, SNS @ElsevierConnect를 통해 최신 소식도 실시간으로 받아보실 수 있습니다.